Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH

27-09-2017 | Image

Figure 4

Human synthetic lethality screens most commonly use either pairs of ‘matched’ or isogenic cell lines of the same background that have only the gene of interest mutated or inactivated (part a) or a panel of genetically diverse cell lines that are split into two groups depending on the status of the gene of interest (part b). After infection with a pool of lentivirus containing gene-specific small interfering RNAs (siRNAs) or single-guide RNAs (sgRNAs), cell populations are grown and next-generation sequencing technologies are used to identify sequences that are underrepresented (or ‘drop out’) solely in the cell line populations that are mutated or inactivated for the gene of interest. Genes targeted by multiple siRNAs or sgRNAs in this subset are candidate synthetic lethal (SL) partners for the gene of interest.

print
PRINT
Image Credits